WEKO3
アイテム
{"_buckets": {"deposit": "f5b6c924-1901-42fc-8834-dc82e6fb9df4"}, "_deposit": {"created_by": 1, "id": "86417", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "86417"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00086417", "sets": ["29"]}, "author_link": ["1054637", "1054656", "1054646", "1054648", "1054650", "1054657", "1054651", "1054641", "1054654", "1054642", "1054647", "1054649", "1054645", "1054655", "1054639", "1054640", "1054653", "1054644", "1054643", "1054652", "1054638"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2022-06-14", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objectives: Metabotropic glutamate receptor 1 (GRM1) is aberrantly overexpressed in a wide variety of human solid tumors, such as melanoma,but not in normal peripheral organs (1). Therefore, GRM1 can be a widely–applicable target for the theranostics in oncology. Here, a novel small-molecular radiopharmaceutical pair, 3-iodo- N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide ([11C]1) and 3-211At-astato-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide ([211At]1), was designed and developed to target the GRM1 for the theranostics in melanomas (Fig.1). \n\nMethod: [ 11C]1 was synthesized by reacting a N-desmethyl precursor with [11C]CH3OTf in the presence of NaOH at room temperature for 5 min. Radiolabeling of [211At]1 was performed by reaction of aryl tin precursor with NCS-containing 211At/MeOH solution. The theranostic potentials of the radiopharmaceutical pair were explored for PET imaging and radiotherapy in GRM1-positive B16F10 melanoma-bearing mice. \n\nResults: [ 11C]1 and [211At]1 were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 19 ± 8 % and 46 ± 3%, respectively, based on the total radioactivity of used radionuclides. In vivo PET imaging of [ 11C]1 clearly visualized the targeted melanomas with a good tumor-to-background contrast (Fig. 1A). Ex vivo biodistribution study verified the persistent increase of [ 11C]1, which reached 12.29 ± 2.44 %ID/g tissue at 90 min in the targeted melanomas, and rapidly cleared from nontarget organs after intravenous injection. In the therapeutic studies, [211At]1 exhibited unequivocal and durable antitumor efficacy with only a single treatment (2.96 MBq) in the melanoma model, compared to the controls (0.38 ± 0.02 cm3 vs. 7.88 ± 1.28 cm3 at 13 days post-therapy) (Fig. 1B). No decrease in body weight, and no liver and kidney damage were observed through the examination period in melanoma mice injected with 2.96 MBq of [211At]1. \n\nConclusion: The novel small-molecular radiopharmaceutical pair successfully visualized the GRM1-positive melanomas by [ 11C]1 with high contrast PET images, and further treated by [211At]1 without significant toxicity. The results highlight the good potential of using [ 11C]1 and [211At]1 as theranostic agents for the management of GRM1-positive tumors and should be further investigated in the theranostic field of oncology in the clinic. ", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": "SNMMI2022", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Lin, Xie"}], "nameIdentifiers": [{"nameIdentifier": "1054637", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Hanyu"}], "nameIdentifiers": [{"nameIdentifier": "1054638", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Fujinaga"}], "nameIdentifiers": [{"nameIdentifier": "1054639", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Lulu"}], "nameIdentifiers": [{"nameIdentifier": "1054640", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding"}], "nameIdentifiers": [{"nameIdentifier": "1054641", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakana, Mori"}], "nameIdentifiers": [{"nameIdentifier": "1054642", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu"}], "nameIdentifiers": [{"nameIdentifier": "1054643", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyuki, Minegishi"}], "nameIdentifiers": [{"nameIdentifier": "1054644", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kotaro, Nagatsu"}], "nameIdentifiers": [{"nameIdentifier": "1054645", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kazunori, Kawamura"}], "nameIdentifiers": [{"nameIdentifier": "1054646", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "1054647", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Lin, Xie", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054648", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Hanyu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054649", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masayuki, Fujinaga", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054650", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Yiding", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054651", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakana, Mori", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054652", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kuan, Hu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054653", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuyuki, Minegishi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054654", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kotaro, Nagatsu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054655", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kazunori, Kawamura", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054656", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "1054657", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair ", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair "}]}, "item_type_id": "10005", "owner": "1", "path": ["29"], "permalink_uri": "https://repo.qst.go.jp/records/86417", "pubdate": {"attribute_name": "公開日", "attribute_value": "2022-05-02"}, "publish_date": "2022-05-02", "publish_status": "0", "recid": "86417", "relation": {}, "relation_version_is_last": true, "title": ["Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair "], "weko_shared_id": -1}
Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair
https://repo.qst.go.jp/records/86417
https://repo.qst.go.jp/records/864172bd64f97-d5c9-4c23-9539-aac9cb069271
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2022-05-02 | |||||
タイトル | ||||||
タイトル | Theranostics of melanoma targeting metabotropic glutamate receptor 1 with a novel small-molecular radiopharmaceutical pair | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Lin, Xie
× Lin, Xie× Masayuki, Hanyu× Masayuki, Fujinaga× Zhang, Lulu× Zhang, Yiding× Wakana, Mori× Kuan, Hu× Katsuyuki, Minegishi× Kotaro, Nagatsu× Kazunori, Kawamura× Zhang, Ming-Rong× Lin, Xie× Masayuki, Hanyu× Masayuki, Fujinaga× Zhang, Yiding× Wakana, Mori× Kuan, Hu× Katsuyuki, Minegishi× Kotaro, Nagatsu× Kazunori, Kawamura× Zhang, Ming-Rong |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Objectives: Metabotropic glutamate receptor 1 (GRM1) is aberrantly overexpressed in a wide variety of human solid tumors, such as melanoma,but not in normal peripheral organs (1). Therefore, GRM1 can be a widely–applicable target for the theranostics in oncology. Here, a novel small-molecular radiopharmaceutical pair, 3-iodo- N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-[11C]methylbenzamide ([11C]1) and 3-211At-astato-N-[4-[6-(methylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide ([211At]1), was designed and developed to target the GRM1 for the theranostics in melanomas (Fig.1). Method: [ 11C]1 was synthesized by reacting a N-desmethyl precursor with [11C]CH3OTf in the presence of NaOH at room temperature for 5 min. Radiolabeling of [211At]1 was performed by reaction of aryl tin precursor with NCS-containing 211At/MeOH solution. The theranostic potentials of the radiopharmaceutical pair were explored for PET imaging and radiotherapy in GRM1-positive B16F10 melanoma-bearing mice. Results: [ 11C]1 and [211At]1 were obtained with a radiochemical purity of greater than 99% and radiochemical yields of 19 ± 8 % and 46 ± 3%, respectively, based on the total radioactivity of used radionuclides. In vivo PET imaging of [ 11C]1 clearly visualized the targeted melanomas with a good tumor-to-background contrast (Fig. 1A). Ex vivo biodistribution study verified the persistent increase of [ 11C]1, which reached 12.29 ± 2.44 %ID/g tissue at 90 min in the targeted melanomas, and rapidly cleared from nontarget organs after intravenous injection. In the therapeutic studies, [211At]1 exhibited unequivocal and durable antitumor efficacy with only a single treatment (2.96 MBq) in the melanoma model, compared to the controls (0.38 ± 0.02 cm3 vs. 7.88 ± 1.28 cm3 at 13 days post-therapy) (Fig. 1B). No decrease in body weight, and no liver and kidney damage were observed through the examination period in melanoma mice injected with 2.96 MBq of [211At]1. Conclusion: The novel small-molecular radiopharmaceutical pair successfully visualized the GRM1-positive melanomas by [ 11C]1 with high contrast PET images, and further treated by [211At]1 without significant toxicity. The results highlight the good potential of using [ 11C]1 and [211At]1 as theranostic agents for the management of GRM1-positive tumors and should be further investigated in the theranostic field of oncology in the clinic. |
|||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | SNMMI2022 | |||||
発表年月日 | ||||||
日付 | 2022-06-14 | |||||
日付タイプ | Issued |